Refine
Has Fulltext
- yes (26) (remove)
Is part of the Bibliography
- yes (26)
Year of publication
Document Type
- Journal article (26)
Language
- English (26)
Keywords
- colorectal cancer (5)
- CRC (2)
- Germany (2)
- MIZ1 (2)
- MYC (2)
- Rectal cancer (2)
- cancer (2)
- chemotherapy (2)
- complication (2)
- therapy (2)
- 5-fluorouracil (1)
- BM (1)
- CCR7 (1)
- COVID-19 pandemic (1)
- CX5461 (1)
- Chirurgie (1)
- Cushing (1)
- FWGE (1)
- HUWE1 (1)
- Improved survival (1)
- LAMN (1)
- Laparoscopy (1)
- Lymph nodes (1)
- MAPK signaling cascades (1)
- MTL30 (1)
- Minimally invasive surgery (1)
- Oncology (1)
- RNAPOL1 (1)
- Radiochemotherapy (1)
- SSI (1)
- Surgery (1)
- Surgical and invasive medical procedures (1)
- Surgical oncology (1)
- TME (1)
- Time interval (1)
- ZfKD (1)
- abdominal surgery (1)
- acute appendicitis (1)
- adjuvant (1)
- adrenal surgery (1)
- adrenal tumors (1)
- adrenalectomia (1)
- adrenocortical adenocarcinoma (1)
- adrenocortical carcinoma (1)
- antibiotics (1)
- appendectomy (1)
- appendicitis (1)
- appendix (1)
- autophagy (1)
- benzoquinone (1)
- bladder (1)
- brain metastases (1)
- caco-2 cells (1)
- cancer cells (1)
- cancer diagnosis (1)
- capture (1)
- carcinomas (1)
- catheterization (1)
- catheters (1)
- cerebral metastases (1)
- chemokine receptor (1)
- colon (1)
- colon cancer (1)
- colon resection (1)
- colorectal carcinoma (1)
- complications (1)
- conventional laparoscopic appendectomy (1)
- cost-effectiveness (1)
- cytostatic (1)
- cytotoxicity (1)
- definition (1)
- digestive system (1)
- discharge definition (1)
- drug discovery (1)
- epidemiology (1)
- epidural block (1)
- gastric cancer (1)
- geriatric (1)
- laparoscopic appendectomy (1)
- laparoscopic right colectomy (1)
- left hemicolectomy (1)
- low-grade mucinous neoplasm (1)
- lymph nodes (1)
- meta-analysis (1)
- metastasis (1)
- mortality (1)
- multimodal (1)
- neoadjuvant (1)
- neuroblastoma – diagnosis (1)
- octogenerians (1)
- open appendectomy (1)
- organoid (1)
- outcome (1)
- oxaliplatin (1)
- pancreatectomy (1)
- patient-derived organoid (PDOs) (1)
- patient-derived tumor organoid (PDTO) (1)
- pediatric (1)
- pediatric adrenocortical adenoma (1)
- pediatric adrenocortical cancer (1)
- pediatric adrenocortical tumor (1)
- pharmacology (1)
- postoperative inflammation (1)
- prognostic factors (1)
- protein expression (1)
- protein synthesis (1)
- reactivating p53 and inducing tumor apoptosis (RITA) (1)
- reactive oxygen species (1)
- rectum (1)
- ribosome (1)
- risk factor (1)
- robotic surgery (1)
- single-port appendectomy (1)
- small interferring RNA (1)
- superior (1)
- surgery (1)
- surgical and invasive medical procedures (1)
- surgical care (1)
- surgical site infection (1)
- survival (1)
- systematic review (1)
- translation initiation (1)
- tumor disease (1)
- ubiquitination (1)
- urinary tract infections (1)
- volume (1)
- wound infection (1)
Institute
- Theodor-Boveri-Institut für Biowissenschaften (26) (remove)
Clinical prognosis of metastasized colorectal carcinoma (CRC) is still not at desired levels and novel drugs are needed. Here, we focused on the multi-tyrosine kinase inhibitor E7080 (Lenvatinib) and assessed its therapeutic efficacy against human CRC cell lines in vitro and human CRC xenografts in vivo. The effect of E7080 on cell viability was examined on 10 humanCRCcell lines and humanendothelial cells (HUVEC). The inhibitory effect of E7080 on VEGF-induced angiogenesis was studied in an ex vivo mouse aortic ring angiogenesis assay. In addition, the efficacy of E7080 against xenografts derived fromCRC cell lines and CRC patient resection specimenswithmutated KRASwas investigated in vivo. Arelatively low cytotoxic effect of E7080 on CRC cell viabilitywas observed in vitro. Endothelial cells (HUVEC)weremore susceptible to the incubation with E7080. This is in line with the observation that E7080 demonstrated an anti-angiogenic effect in a three-dimensional ex vivo mouse aortic ring angiogenesis assay. E7080 effectively disrupted CRC cell-mediated VEGF-stimulated growth of HUVEC in vitro. Daily in vivo treatment with E7080 (5 mg/kg) significantly delayed the growth of KRAS mutated CRC xenografts with decreased density of tumor-associated vessel formations and without tumor regression. This observation is in line with results that E7080 did not significantly reduce the number of Ki67-positive cells in CRC xenografts. The results suggest antiangiogenic activity of E7080 at a dosage thatwas well tolerated by nudemice. E7080 may provide therapeutic benefits in the treatment of CRC with mutated KRAS.